

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Mealey and Bentjen

Art Unit: Not yet assigned

Application No. 10/044,671

CERTIFICATE OF MAILING

Filed: January 10, 2002

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service on February 25, 2002, as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, WASHINGTON D.C. 20231.

For: MDR1 VARIANTS AND METHODS FOR THEIR USE

Examiner: Not yet assigned

Date: February 25, 2002

Tanya M. Harding, Ph.D.
Attorney for Applicant

TRANSMITTAL LETTER

COMMISSIONER FOR PATENTS
WASHINGTON, DC 20231

Enclosed for filing in the application referenced above are the following:

- ☒ Information Disclosure Statement
- ☒ Form 1449 and 33 references cited thereon
- ☒ Small entity status is claimed for this application.
- ☒ The Director is hereby authorized to charge any additional fees that may be required, or credit over-payment, to Account No. 02-4550. A copy of this sheet is enclosed.
- ☒ Please return the enclosed postcard to confirm that the items listed above have been received.

Respectfully submitted,
KLARQUIST SPARKMAN, LLP

By

Tanya M. Harding, Ph.D.
Registration No. 42,630

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391 Facsimile: (503) 228-9446
cc: Docketing



TMH:kam:jlh 02/25/02 4630-61733 92452

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re application of: Mealey and Bentjen

Application No. 10/044,671

Filed: January 10, 2002

For: MDR1 VARIANTS AND METHODS FOR
THEIR USE

Examiner: Not yet assigned

Date: February 25, 2002

Art Unit: Not yet assigned

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service on February 25, 2002 as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231.

Tanya M. Harding, Ph.D.
Attorney for Applicant

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97(b)(3)

COMMISSIONER FOR PATENTS
WASHINGTON, DC 20231

Sir:

Listed on the accompanying form PTO-1449 and enclosed herewith are a number of English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent.

Applicants filed this Information Disclosure Statement ("IDS") before the mailing date of a first Office action on the merits. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicants to file this Information Disclosure Statement, please see the attached transmittal letter for Deposit Account authority.


Respectfully submitted,

KLARQUIST SPARKMAN, LLP


By

Tanya M. Harding, Ph.D.
Registration No. 42,630

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446

INFORMATION DISCLOSURE STATEMENT  BY APPLICANT				Docket: 4630-61733		App: 10/044,671	
				Applicant: Mealey and Bentjen			
				Filed: January 10, 2002		Art Unit: Not yet assigned	
U.S. PATENT DOCUMENTS							
Init.*		Number	Date	Name	Class	Sub	Filed
		5,583,008	Dec 10, 1996	Johnson <i>et al</i>			
FOREIGN PATENT DOCUMENTS							
Init.*		Number	Date	Country	Class	Sub	
		WO 94/26115	Nov 24, 1994	WIPO (PCT)			
		WO 98/13072	Apr 2, 1998	WIPO (PCT)			
		WO 98/14615	Apr 9, 1998	WIPO (PCT)			
		WO 00/46347	Aug 10, 2000	WIPO (PCT)			
		WO 00/52144	Sep 8, 2000	WIPO (PCT)			
		WO 01/09183	Feb 8, 2001	WIPO (PCT)			
OTHER DOCUMENTS							
Init.*		Citation					
		Brown <i>et al</i> , "Changes in the use profile of Mectizan: 1987-1997," <i>Journals of Tropical Medicine & Parasitology</i> 92(1):S61-S64, 1998					
		Campbell <i>et al</i> , "Molecular cloning and characterization of canine metalloproteinase-9 gene promoter," <i>Gene</i> 273(1):81-87, 2001 ABSTRACT ONLY					
		Carver <i>et al</i> , "Mutagenicity Testing in Mammalian Cells," <i>Mutation Research</i> 72:207-230, 1980					


EXAMINER:	DATE
*Examiner: Initial if considered, whether or not in conformance with MPEP 609; draw line through cite if not in conformance and not considered. Send copy.	

 <p align="center">INFORMATION DISCLOSURE STATEMENT</p> <p align="center">BY APPLICANT</p>			Docket: 4630-61733	App: Not yet assigned
			Applicant: Mealey and Bentjen	
			Filed: January 10, 2002	Art Unit: Not yet assigned
Init.*		Citation		
		Decleves <i>et al</i> , "A new polymorphism (N21D) in the exon 2 of the human MDR1 gene encoding the P-glycoprotein," <i>Human Mutation</i> 15(5):486, 2000		
		Fassler <i>et al</i> , "Evaluation of the safety of ivermectin administered in a beef-based formulation to ivermectin-sensitive Collies," <i>J Am Vet Med Assoc</i> 199(4):457-460, 1991 ABSTRACT ONLY		
		Hoerauf <i>et al</i> , "Tetracycline therapy targets intracellular bacteria in the filarial nematode <i>Litomosoides sigmodontis</i> and results in filarial infertility," <i>J Clin Invest</i> 103(1):11-17, 1999		
		Hoffmeyer <i>et al</i> , "Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity <i>in vivo</i> ," <i>PNAS</i> 97(7):3473-3478, 2000		
		Kadoi, "Establishment of a canine monocyte cell line," <i>New Microbiol</i> 23(4):441-444, 2000 ABSTRACT ONLY		
		Kim <i>et al</i> , "The Drug Transporter P-glycoprotein Limits Oral Absorption and Brain Entry of HIV-1 Protease Inhibitors," <i>J Clin Invest</i> 101(2):289-294, 1998		
		Knutsen <i>et al</i> , "Cytogenetic and molecular characterization of random chromosomal rearrangements activating the drug resistance gene, <i>MDR1/P-glycoprotein</i> , in drug-selected cell lines and patients with drug refractory ALL," <i>Genes, Chromosomes and Cancer</i> 23(1):44-54, 1998 ABSTRACT ONLY		
		Lankas <i>et al</i> , "P-Glycoprotein Deficiency in a Subpopulation of CF-1 Mice Enhances Avermectin-Induced Neurotoxicity," <i>Toxicology and Applied Pharmacology</i> 143:357-365, 1997		

EXAMINER:

DATE

*Examiner: Initial if considered, whether or not in conformance with MPEP 609; draw line through cite if not in conformance and not considered. Send copy.



INFORMATION DISCLOSURE STATEMENT

BY APPLICANT

Docket: 4630-61733

App: Not yet assigned

Applicant: Mealey and Bentjen

Filed: January 10, 2002


Art Unit: Not yet assigned

Init.*			Citation
			Martinez <i>et al</i> , "Neuromuscular Effects of Doxacurium Chloride in Isoflurane-Anesthetized Dogs," <i>Veterinary Surgery</i> 27:279-283, 1998 ABSTRACT ONLY
			Mayer <i>et al</i> , "Full Blockade of Intestinal P-glycoprotein and Extensive Inhibition of Blood-brain Barrier P-glycoprotein by Oral Treatment of Mice with PSC833," <i>J Clin Invest</i> 100(10):2430-2436, 1997
			Paul <i>et al</i> , "Clinical observations in collies given ivermectin orally," <i>Am J Vet Res</i> 48(4):684-685, 1987 ABSTRACT ONLY
			Rohrer and Evans, "Binding characteristics of ivermectin in plasma from collie dogs," <i>Vet Res Commun</i> 14(2):157-165, 1990 ABSTRACT ONLY
			Schinkel <i>et al</i> , "Absence of the mdrla P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporine A," <i>J Clin Invest</i> 96(4):1698-1705, 1995 ABSTRACT ONLY
			Schinkel <i>et al</i> , "P-Glycoprotein in the Blood-Brain Barrier of Mice Influences the Brain Penetration and Pharmacological Activity of Many Drugs," <i>J Clin Invest</i> 97(11):2517-2524, 1996
			Smit <i>et al</i> , "Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure," <i>J Clin Invest</i> 104(10):1441-1447, 1999
			Smith <i>et al</i> , "P-Glycoprotein Efflux at the Blood-Brain Barrier Mediates Differences in Brain Disposition and Pharmacodynamics between Two Structurally Related Neurokinin-1 Receptor Antagonists," <i>JPET</i> 298(3):1252-1259, 2001
			Suzuki and Sugiyama, "Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine," <i>Euro. J. Pharma. Sci.</i> 12:3-12, 2000

EXAMINER:

DATE

*Examiner: Initial if considered, whether or not in conformance with MPEP 609; draw line through cite if not in conformance and not considered. Send copy.



INFORMATION DISCLOSURE STATEMENT

BY APPLICANT

Docket: 4630-61733

App: Not yet assigned

Applicant: Mealey and Bentjen

Filed: January 10, 2002

Art Unit: Not yet
assigned

Init.*	Citation	
		Tranquilli <i>et al</i> , "Ivermectin plasma concentrations in collies sensitive to ivermectin-induced toxicosis," <i>Am J Vet Res</i> 50(5):769-770, 1989 ABSTRACT ONLY
		Umbenhauer <i>et al</i> , "Identification of a P-Glycoprotein-Deficient Subpopulation in the CF-1 Mouse Strain Using a Restriction Fragment Length Polymorphism," <i>Toxic. Appl. Pharma.</i> 146:88-94, 1997
		Vaughn <i>et al</i> , "Determination of homovanillic acid, 5-hydroxyindoleacetic acid and pressure in the cerebrospinal fluid of collie dogs following administration of ivermectin," <i>Vet Res Commun</i> 13(1):47-55, 1989 ABSTRACT ONLY
		http://www.dog-tracker.com/forums/vet/messages/10052.shtml , 7 pages, printed 11/18/2000
		http://www.faqs.org/faqs/dogs-faq/breeds/collies , 2 pages, printed 11/18/2000
		http://www.golden-retriever.com/heartworm.html , 4 pages, printed 11/18/2000

EXAMINER:

DATE

*Examiner: Initial if considered, whether or not in conformance with MPEP 609; draw line through cite if not in conformance and not considered. Send copy.